IMI AMR ACCELERATOR
@amr-accelerator.bsky.social
The AMR Accelerator is progressing the development of new medicines to treat or prevent resistant bacterial infections.
- 9 Projects Tackling Antibiotic Resistance Together -
Visit our website at https://amr-accelerator.eu/
- 9 Projects Tackling Antibiotic Resistance Together -
Visit our website at https://amr-accelerator.eu/
Pinned
We are bringing you our latest webinar on Hollow Fibre Assays in antimicrobial drug development, featuring three leading experts.
👉 𝗟𝗲𝗮𝗿𝗻 𝗮𝗯𝗼𝘂𝘁:
Building effective hollow fibre systems
Case studies
Applications in 𝘪𝘯-𝘷𝘪𝘵𝘳𝘰 PK/PD models
👉 Register now: https://bit.ly/3VN3Sa5
👉 𝗟𝗲𝗮𝗿𝗻 𝗮𝗯𝗼𝘂𝘁:
Building effective hollow fibre systems
Case studies
Applications in 𝘪𝘯-𝘷𝘪𝘵𝘳𝘰 PK/PD models
👉 Register now: https://bit.ly/3VN3Sa5
𝗪𝗲𝗯𝗶𝗻𝗮𝗿 𝗥𝗲𝗴𝗶𝘀𝘁𝗿𝗮𝘁𝗶𝗼𝗻 𝗜𝘀 𝗡𝗼𝘄 𝗢𝗽𝗲𝗻!! Reserve your spot today for the upcoming COMBINE-GNA NOW and webinar on i𝘯 𝘷𝘪𝘵𝘳𝘰 standardisation in antimicrobial drug development.
Register now to secure your spot: https://bit.ly/4nQvPsR
Register now to secure your spot: https://bit.ly/4nQvPsR
November 11, 2025 at 7:30 AM
𝗪𝗲𝗯𝗶𝗻𝗮𝗿 𝗥𝗲𝗴𝗶𝘀𝘁𝗿𝗮𝘁𝗶𝗼𝗻 𝗜𝘀 𝗡𝗼𝘄 𝗢𝗽𝗲𝗻!! Reserve your spot today for the upcoming COMBINE-GNA NOW and webinar on i𝘯 𝘷𝘪𝘵𝘳𝘰 standardisation in antimicrobial drug development.
Register now to secure your spot: https://bit.ly/4nQvPsR
Register now to secure your spot: https://bit.ly/4nQvPsR
Innovative science alone will not end TB, it is just the start. True impact needs trials, policies and real-world action. UNITE4TB interviewed stakeholders to understand challenges & opportunities in turning TB innovation into real impact.
Read complete paper at: https://bit.ly/4pe6GtB
Read complete paper at: https://bit.ly/4pe6GtB
November 6, 2025 at 7:30 AM
Innovative science alone will not end TB, it is just the start. True impact needs trials, policies and real-world action. UNITE4TB interviewed stakeholders to understand challenges & opportunities in turning TB innovation into real impact.
Read complete paper at: https://bit.ly/4pe6GtB
Read complete paper at: https://bit.ly/4pe6GtB
Want to stay up to date with the project updates ?
Our upcoming newsletter is the easiest way! 📰
Every edition will bring you:
✅ Latest project updates
✅ Exclusive interviews with our researchers
✅ Insights into the latest advances in tackling AMR
👉 Sign up now: https://bit.ly/4qDXxMj
Our upcoming newsletter is the easiest way! 📰
Every edition will bring you:
✅ Latest project updates
✅ Exclusive interviews with our researchers
✅ Insights into the latest advances in tackling AMR
👉 Sign up now: https://bit.ly/4qDXxMj
November 4, 2025 at 7:30 AM
Want to stay up to date with the project updates ?
Our upcoming newsletter is the easiest way! 📰
Every edition will bring you:
✅ Latest project updates
✅ Exclusive interviews with our researchers
✅ Insights into the latest advances in tackling AMR
👉 Sign up now: https://bit.ly/4qDXxMj
Our upcoming newsletter is the easiest way! 📰
Every edition will bring you:
✅ Latest project updates
✅ Exclusive interviews with our researchers
✅ Insights into the latest advances in tackling AMR
👉 Sign up now: https://bit.ly/4qDXxMj
In the EU/EEA, drug-resistant infections costs nearly EUR 11.7B per year.
This is not just statistics but a call to act. Latest study under PrIMAVeRa shows just how big the burden is, both for health and for cost.
👉 Read the complete paper at: https://bit.ly/46VoQsf
This is not just statistics but a call to act. Latest study under PrIMAVeRa shows just how big the burden is, both for health and for cost.
👉 Read the complete paper at: https://bit.ly/46VoQsf
October 30, 2025 at 7:29 AM
In the EU/EEA, drug-resistant infections costs nearly EUR 11.7B per year.
This is not just statistics but a call to act. Latest study under PrIMAVeRa shows just how big the burden is, both for health and for cost.
👉 Read the complete paper at: https://bit.ly/46VoQsf
This is not just statistics but a call to act. Latest study under PrIMAVeRa shows just how big the burden is, both for health and for cost.
👉 Read the complete paper at: https://bit.ly/46VoQsf
One of the major reason for unsuccessful outcomes are the adverse events (AEs) from TB medications, which can disrupt treatment and reduce success rates. Dr. Simon Tiberi shared practical advice for healthcare teams to prevent treatment interruptions.
Learn more: https://bit.ly/4qqxfgu
Learn more: https://bit.ly/4qqxfgu
October 28, 2025 at 7:25 AM
One of the major reason for unsuccessful outcomes are the adverse events (AEs) from TB medications, which can disrupt treatment and reduce success rates. Dr. Simon Tiberi shared practical advice for healthcare teams to prevent treatment interruptions.
Learn more: https://bit.ly/4qqxfgu
Learn more: https://bit.ly/4qqxfgu
In our latest study, under UNITE4TB we explore how biomarkers are closing the gap, particularly in challenging cases such as low bacterial load, inability to produce sputum or smear-negative TB.
👉 Read full paper at: https://bit.ly/4ohCFZn
👉 Read full paper at: https://bit.ly/4ohCFZn
October 23, 2025 at 6:30 AM
In our latest study, under UNITE4TB we explore how biomarkers are closing the gap, particularly in challenging cases such as low bacterial load, inability to produce sputum or smear-negative TB.
👉 Read full paper at: https://bit.ly/4ohCFZn
👉 Read full paper at: https://bit.ly/4ohCFZn
Webinar registration is now open! Join COMBINE, ERA4TB & GNANOW on October 21, Tuesday from 15:00–16:30 CEST for insights on Hollow Fiber Assays in antimicrobial drug development with three experts, Prof. Das, S. Ramon-Garcia & Prof. MacGowan.
👉 Register now: https://bit.ly/3VN3Sa5
👉 Register now: https://bit.ly/3VN3Sa5
October 21, 2025 at 6:23 AM
Webinar registration is now open! Join COMBINE, ERA4TB & GNANOW on October 21, Tuesday from 15:00–16:30 CEST for insights on Hollow Fiber Assays in antimicrobial drug development with three experts, Prof. Das, S. Ramon-Garcia & Prof. MacGowan.
👉 Register now: https://bit.ly/3VN3Sa5
👉 Register now: https://bit.ly/3VN3Sa5
Our latest research under @era4tb.bsky.social, highlights that small adjustments in the hollow fiber assays better reflects how TB drugs really perform.
Learn more through a webinar on 21 October 2025.
👉 Research paper: https://bit.ly/4q7jIKE
👉 Webinar registration: https://bit.ly/3VN3Sa5
Learn more through a webinar on 21 October 2025.
👉 Research paper: https://bit.ly/4q7jIKE
👉 Webinar registration: https://bit.ly/3VN3Sa5
October 16, 2025 at 6:50 AM
Our latest research under @era4tb.bsky.social, highlights that small adjustments in the hollow fiber assays better reflects how TB drugs really perform.
Learn more through a webinar on 21 October 2025.
👉 Research paper: https://bit.ly/4q7jIKE
👉 Webinar registration: https://bit.ly/3VN3Sa5
Learn more through a webinar on 21 October 2025.
👉 Research paper: https://bit.ly/4q7jIKE
👉 Webinar registration: https://bit.ly/3VN3Sa5
The COMBINE consortium met in Toulouse for its sixth annual meeting and focus is now on making our AMR Accelerator impact last. How do we plan to do that? By keeping datasets FAIR, preserving consortium expertise and embedding results in European & global research infrastructures.
October 14, 2025 at 6:30 AM
The COMBINE consortium met in Toulouse for its sixth annual meeting and focus is now on making our AMR Accelerator impact last. How do we plan to do that? By keeping datasets FAIR, preserving consortium expertise and embedding results in European & global research infrastructures.
In our latest study under RespiriNTM, zebra fish helped our researchers model nontuberculous mycobacterial infection.
Why?
Their immune system mirrors humans, letting us study infections effectively and ethically.
👉 Read more at: https://bit.ly/4pS8HwB
👉 Open manuscript: https://bit.ly/3KzNEi8
Why?
Their immune system mirrors humans, letting us study infections effectively and ethically.
👉 Read more at: https://bit.ly/4pS8HwB
👉 Open manuscript: https://bit.ly/3KzNEi8
October 9, 2025 at 6:30 AM
In our latest study under RespiriNTM, zebra fish helped our researchers model nontuberculous mycobacterial infection.
Why?
Their immune system mirrors humans, letting us study infections effectively and ethically.
👉 Read more at: https://bit.ly/4pS8HwB
👉 Open manuscript: https://bit.ly/3KzNEi8
Why?
Their immune system mirrors humans, letting us study infections effectively and ethically.
👉 Read more at: https://bit.ly/4pS8HwB
👉 Open manuscript: https://bit.ly/3KzNEi8
We are bringing you our latest webinar on Hollow Fibre Assays in antimicrobial drug development, featuring three leading experts.
👉 𝗟𝗲𝗮𝗿𝗻 𝗮𝗯𝗼𝘂𝘁:
Building effective hollow fibre systems
Case studies
Applications in 𝘪𝘯-𝘷𝘪𝘵𝘳𝘰 PK/PD models
👉 Register now: https://bit.ly/3VN3Sa5
👉 𝗟𝗲𝗮𝗿𝗻 𝗮𝗯𝗼𝘂𝘁:
Building effective hollow fibre systems
Case studies
Applications in 𝘪𝘯-𝘷𝘪𝘵𝘳𝘰 PK/PD models
👉 Register now: https://bit.ly/3VN3Sa5
October 7, 2025 at 6:30 AM
We are bringing you our latest webinar on Hollow Fibre Assays in antimicrobial drug development, featuring three leading experts.
👉 𝗟𝗲𝗮𝗿𝗻 𝗮𝗯𝗼𝘂𝘁:
Building effective hollow fibre systems
Case studies
Applications in 𝘪𝘯-𝘷𝘪𝘵𝘳𝘰 PK/PD models
👉 Register now: https://bit.ly/3VN3Sa5
👉 𝗟𝗲𝗮𝗿𝗻 𝗮𝗯𝗼𝘂𝘁:
Building effective hollow fibre systems
Case studies
Applications in 𝘪𝘯-𝘷𝘪𝘵𝘳𝘰 PK/PD models
👉 Register now: https://bit.ly/3VN3Sa5
Medicines need a reliable teammate to work effectively against resistant bacteria.
And Alpibectir is that teammate boosting ethionamide (Eto) to fight resistant bacteria.
👉 Read the complete paper to see the impact of Alpibectir in a first-in-human TRIC-TB study: https://bit.ly/48c5odi
And Alpibectir is that teammate boosting ethionamide (Eto) to fight resistant bacteria.
👉 Read the complete paper to see the impact of Alpibectir in a first-in-human TRIC-TB study: https://bit.ly/48c5odi
October 2, 2025 at 6:25 AM
Medicines need a reliable teammate to work effectively against resistant bacteria.
And Alpibectir is that teammate boosting ethionamide (Eto) to fight resistant bacteria.
👉 Read the complete paper to see the impact of Alpibectir in a first-in-human TRIC-TB study: https://bit.ly/48c5odi
And Alpibectir is that teammate boosting ethionamide (Eto) to fight resistant bacteria.
👉 Read the complete paper to see the impact of Alpibectir in a first-in-human TRIC-TB study: https://bit.ly/48c5odi
Reposted by IMI AMR ACCELERATOR
ERA4TB Webinar 📣
How can health systems respond to #AMR through innovation & evidence-based policy? 🌍✨
🗓️ 8 Oct 2025 | 1–2pm UK | 2–3pm CEST
🎙️ Speakers from NICE & WHO
👉 Register: tinyurl.com/ERA4TB
@amr-accelerator.bsky.social @amr-accelerator.bsky.social @tballiance.bsky.social
How can health systems respond to #AMR through innovation & evidence-based policy? 🌍✨
🗓️ 8 Oct 2025 | 1–2pm UK | 2–3pm CEST
🎙️ Speakers from NICE & WHO
👉 Register: tinyurl.com/ERA4TB
@amr-accelerator.bsky.social @amr-accelerator.bsky.social @tballiance.bsky.social
Video Conferencing, Web Conferencing, Webinars, Screen Sharing
Zoom is the leader in modern enterprise video communications, with an easy, reliable cloud platform for video and audio conferencing, chat, and webinars across mobile, desktop, and room systems. Zoom ...
tinyurl.com
September 29, 2025 at 9:50 AM
ERA4TB Webinar 📣
How can health systems respond to #AMR through innovation & evidence-based policy? 🌍✨
🗓️ 8 Oct 2025 | 1–2pm UK | 2–3pm CEST
🎙️ Speakers from NICE & WHO
👉 Register: tinyurl.com/ERA4TB
@amr-accelerator.bsky.social @amr-accelerator.bsky.social @tballiance.bsky.social
How can health systems respond to #AMR through innovation & evidence-based policy? 🌍✨
🗓️ 8 Oct 2025 | 1–2pm UK | 2–3pm CEST
🎙️ Speakers from NICE & WHO
👉 Register: tinyurl.com/ERA4TB
@amr-accelerator.bsky.social @amr-accelerator.bsky.social @tballiance.bsky.social
Our researchers found a missing link in applying ML to AMR: lack of clinical and preclinical data.
We highlighted the key milestones from data collection to ML models in building the first and public FAIR MIC dataset & AntiMicrobial-KG.
Listen to webinar to learn more: bit.ly/472Q8y4
We highlighted the key milestones from data collection to ML models in building the first and public FAIR MIC dataset & AntiMicrobial-KG.
Listen to webinar to learn more: bit.ly/472Q8y4
September 30, 2025 at 8:25 AM
Our researchers found a missing link in applying ML to AMR: lack of clinical and preclinical data.
We highlighted the key milestones from data collection to ML models in building the first and public FAIR MIC dataset & AntiMicrobial-KG.
Listen to webinar to learn more: bit.ly/472Q8y4
We highlighted the key milestones from data collection to ML models in building the first and public FAIR MIC dataset & AntiMicrobial-KG.
Listen to webinar to learn more: bit.ly/472Q8y4
In our latest study, under UNITE4TB consortium, researchers describe how AI could become a powerful ally against TB at the same time highlight challenges that come with this new tech.
👉 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗰𝗼𝗺𝗽𝗹𝗲𝘁𝗲 𝗽𝗮𝗽𝗲𝗿 𝗮𝘁: https://bit.ly/3Is4E9m
👉 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗰𝗼𝗺𝗽𝗹𝗲𝘁𝗲 𝗽𝗮𝗽𝗲𝗿 𝗮𝘁: https://bit.ly/3Is4E9m
September 25, 2025 at 6:30 AM
In our latest study, under UNITE4TB consortium, researchers describe how AI could become a powerful ally against TB at the same time highlight challenges that come with this new tech.
👉 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗰𝗼𝗺𝗽𝗹𝗲𝘁𝗲 𝗽𝗮𝗽𝗲𝗿 𝗮𝘁: https://bit.ly/3Is4E9m
👉 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗰𝗼𝗺𝗽𝗹𝗲𝘁𝗲 𝗽𝗮𝗽𝗲𝗿 𝗮𝘁: https://bit.ly/3Is4E9m
Reposted by IMI AMR ACCELERATOR
ERA4TB Webinar 📣
How can health systems respond to #AMR through innovation & evidence-based policy? 🌍
Join our ERA4TB webinar
🗓️ 8 Oct 2025 | 1–2pm UK | 2–3pm CEST
🎙️ Speakers from @NICEComms & @WHO
👉 Register: tinyurl.com/ERA4TB
@amr-accelerator.bsky.social @who.int @nicecomms.bsky.social
How can health systems respond to #AMR through innovation & evidence-based policy? 🌍
Join our ERA4TB webinar
🗓️ 8 Oct 2025 | 1–2pm UK | 2–3pm CEST
🎙️ Speakers from @NICEComms & @WHO
👉 Register: tinyurl.com/ERA4TB
@amr-accelerator.bsky.social @who.int @nicecomms.bsky.social
September 24, 2025 at 12:21 PM
ERA4TB Webinar 📣
How can health systems respond to #AMR through innovation & evidence-based policy? 🌍
Join our ERA4TB webinar
🗓️ 8 Oct 2025 | 1–2pm UK | 2–3pm CEST
🎙️ Speakers from @NICEComms & @WHO
👉 Register: tinyurl.com/ERA4TB
@amr-accelerator.bsky.social @who.int @nicecomms.bsky.social
How can health systems respond to #AMR through innovation & evidence-based policy? 🌍
Join our ERA4TB webinar
🗓️ 8 Oct 2025 | 1–2pm UK | 2–3pm CEST
🎙️ Speakers from @NICEComms & @WHO
👉 Register: tinyurl.com/ERA4TB
@amr-accelerator.bsky.social @who.int @nicecomms.bsky.social
Collaboration in AMR R&D is multisectoral, but not every question moves a project forward. Early scientific advice from EMA is key to understanding what to ask (and not to).
🎥 Watch the complete webinar at: https://bit.ly/4mpXPTx
🎥 Watch the complete webinar at: https://bit.ly/4mpXPTx
September 23, 2025 at 6:30 AM
Collaboration in AMR R&D is multisectoral, but not every question moves a project forward. Early scientific advice from EMA is key to understanding what to ask (and not to).
🎥 Watch the complete webinar at: https://bit.ly/4mpXPTx
🎥 Watch the complete webinar at: https://bit.ly/4mpXPTx
Reposted by IMI AMR ACCELERATOR
ERA4TB (European Regimen Accelerator for Tuberculosis) project is a public-private initiative devoted to accelerate the development of new treatment regimens for #tuberculosis.
March 7, 2025 at 11:07 AM
ERA4TB (European Regimen Accelerator for Tuberculosis) project is a public-private initiative devoted to accelerate the development of new treatment regimens for #tuberculosis.
Across the EU/EEA, resistant infections add over 9.5M extra hospital days annually. In a study conducted under PrIMAVeRa, our researchers used Bayesian analysis to show each resistant infection adds ~1–2 days, with variable extra costs.
👉 Read more: https://bit.ly/468S1co
👉 Read more: https://bit.ly/468S1co
September 18, 2025 at 6:30 AM
Across the EU/EEA, resistant infections add over 9.5M extra hospital days annually. In a study conducted under PrIMAVeRa, our researchers used Bayesian analysis to show each resistant infection adds ~1–2 days, with variable extra costs.
👉 Read more: https://bit.ly/468S1co
👉 Read more: https://bit.ly/468S1co
Of all the buzzwords this year, none spread faster than "superbugs"! Used in the titles or main public messaging by over half a dozen of major news stories & campaigns (Mar–Sep 2025). Catchy, but does it oversimplify AMR or mislead the public?
Share your thoughts on main drawback of this framing.
Share your thoughts on main drawback of this framing.
September 16, 2025 at 10:00 AM
Of all the buzzwords this year, none spread faster than "superbugs"! Used in the titles or main public messaging by over half a dozen of major news stories & campaigns (Mar–Sep 2025). Catchy, but does it oversimplify AMR or mislead the public?
Share your thoughts on main drawback of this framing.
Share your thoughts on main drawback of this framing.
@era4tb.bsky.social researchers found compounds that block TB’s ESX-1 system (used to damage immune cells) while also improving effectiveness of ethionamide. A dual-action step against drug-resistant TB.
👉 𝗥𝗲𝗮𝗱 𝗺𝗼𝗿𝗲: bit.ly/3VJJJBw
👉 𝗥𝗲𝗮𝗱 𝗺𝗼𝗿𝗲: bit.ly/3VJJJBw
September 11, 2025 at 8:17 AM
@era4tb.bsky.social researchers found compounds that block TB’s ESX-1 system (used to damage immune cells) while also improving effectiveness of ethionamide. A dual-action step against drug-resistant TB.
👉 𝗥𝗲𝗮𝗱 𝗺𝗼𝗿𝗲: bit.ly/3VJJJBw
👉 𝗥𝗲𝗮𝗱 𝗺𝗼𝗿𝗲: bit.ly/3VJJJBw
Why understanding the right dose matters in anti-TB treatment?
We broke it down 👇 for you from the start to finish.
👉 Join the UNITE4TB & ERS webinar to learn more on methods that are being used to understand optimal dosing in depth
🔗 https://bit.ly/45QUyYB
We broke it down 👇 for you from the start to finish.
👉 Join the UNITE4TB & ERS webinar to learn more on methods that are being used to understand optimal dosing in depth
🔗 https://bit.ly/45QUyYB
September 9, 2025 at 6:30 AM
Why understanding the right dose matters in anti-TB treatment?
We broke it down 👇 for you from the start to finish.
👉 Join the UNITE4TB & ERS webinar to learn more on methods that are being used to understand optimal dosing in depth
🔗 https://bit.ly/45QUyYB
We broke it down 👇 for you from the start to finish.
👉 Join the UNITE4TB & ERS webinar to learn more on methods that are being used to understand optimal dosing in depth
🔗 https://bit.ly/45QUyYB
“Supercontactors” are the hubs of hospital networks. Controlling their interactions, can help dramatically slow down the spread. Our latest PrIMAVeRa study showcases that targeting them reduced MRSA cases by about 20%.
👉 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗽𝗮𝗽𝗲𝗿 𝗮𝘁: https://bit.ly/468hBgo
👉 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗽𝗮𝗽𝗲𝗿 𝗮𝘁: https://bit.ly/468hBgo
September 4, 2025 at 6:30 AM
“Supercontactors” are the hubs of hospital networks. Controlling their interactions, can help dramatically slow down the spread. Our latest PrIMAVeRa study showcases that targeting them reduced MRSA cases by about 20%.
👉 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗽𝗮𝗽𝗲𝗿 𝗮𝘁: https://bit.ly/468hBgo
👉 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗽𝗮𝗽𝗲𝗿 𝗮𝘁: https://bit.ly/468hBgo
In AMR research, success rarely comes easy. From LpxH inhibitors under Uppsala University to PhagoMed’s pivot (now BioNTech) and Disperazol’s 15-year journey, each story shows how barriers can be turned into pathways for progress.
👉 Hear their lessons and takeaways here: https://bit.ly/47n6d2v
👉 Hear their lessons and takeaways here: https://bit.ly/47n6d2v
September 2, 2025 at 6:30 AM
In AMR research, success rarely comes easy. From LpxH inhibitors under Uppsala University to PhagoMed’s pivot (now BioNTech) and Disperazol’s 15-year journey, each story shows how barriers can be turned into pathways for progress.
👉 Hear their lessons and takeaways here: https://bit.ly/47n6d2v
👉 Hear their lessons and takeaways here: https://bit.ly/47n6d2v
TB bacteria inhabits the air we breathe, exposing most people unknowingly. Yet only 5–10% develop active disease. Research under RespiriNTM and RespiriTB tested amiodarone, to boost immunity by enhancing autophagy against TB.
👉 Read: https://bit.ly/47QD53J
👉 Read: https://bit.ly/47QD53J
August 28, 2025 at 6:30 AM
TB bacteria inhabits the air we breathe, exposing most people unknowingly. Yet only 5–10% develop active disease. Research under RespiriNTM and RespiriTB tested amiodarone, to boost immunity by enhancing autophagy against TB.
👉 Read: https://bit.ly/47QD53J
👉 Read: https://bit.ly/47QD53J